Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
Nexalin signed a definitive 10-year exclusive distribution agreement with Inovanexa Medical Technologies covering seven South American countries and more than 300 million people for the ANVISA-approved Nexalin Sync device. The distributor placed a binding initial order for 10 devices with 5 delivered at signing, and a 100-device commercialization program plus a clinical pilot targeted within 90 days; after 30 devices, the distributor must build a locally funded Brazil manufacturing facility, with Nexalin earning per-device compensation and per-unit royalties on disposables.
Key figures
- Agreement term years
- 10
- Territory population
- more than 300 million
- Anxiety response rate
- 77.8%
- Commercialization devices
- 100
- Clinical pilot target days
- 90
- Devices delivered immediately
- 5
- Initial binding order devices
- 10
- Brazil mental health disorders
- more than 35 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.